Is primary Sjögren’s syndrome a risk factor for malignancies different from lymphomas? What does the literature highlight about it?
Data nadesłania: 01-04-2017
Data ostatniej rewizji: 14-05-2017
Data akceptacji: 12-06-2017
Data publikacji online: 18-07-2017
Data publikacji: 30-06-2017
Reumatologia 2017;55(3):136-139
Background: Primary Sjögren’s syndrome (pSS) is a chronic systemic autoimmune disease with an elevated risk of developing lymphoproliferative malignancies (LM). Whether pSS is a risk factor or not for non-lymphoma malignancies (NLM) has been scarcely evaluated in the literature. Age is per se a risk factor for malignancies: patients over 70 years old have 4 times higher risk for cancers than adults. Even if the mean age of pSS onset usually is in the 4th and 5th decade, its onset in patients aged over 65 years (Elderly Onset pSS – EOpSS) is not uncommon.
Material and methods: To evaluate pSS as a risk factor for NLM we performed a systematic electronic search on PubMed in the period 2006–2016 to identify all the publications on this topic. The studies were eligible for inclusion if they reported specific Standardized Incidence Ratio (SIR) with 95% CI. Studies that did not report sufficient published and/or original data were excluded.
Results: Only 7 articles of 494 that we found in PubMed fulfilled the inclusion criterion. In the vast majority of these, SIR values were not statistically significant for NLM. The occurrence of NLM after LM was statistically significant in some studies and a NLM represented the most frequent cause of death. The possibility that NLM may represent a paraneoplastic syndrome seems much more frequent than LM, the risk of which increases with time after the diagnosis. Data regarding the neoplastic weight of EOpSS are mainly pointed out by case reports.
Conclusions: Primary Sjögren’s syndrome is not associated with an increased risk for NLM. However the possibility that NLM may appear after recovery from lymphoma should be carefully considered because it could be cause of the patient’s death. Similarly the possibility that NLM may represent a paraneoplastic syndrome must be highlighted. The relationship between EOpSS and SIRs for NLM should be deepened with studies on ad hoc cohorts.
Sjögren H. Zur Kenntnis der Keratoconjunctivitis Sicca. Acta Ophtalmol (Copenh) 1933; Suppl. 2: 1-51.
Patel R, Shahane A. The epidemiology of Sjögren’s syndrome. Clin Epidemiol 2014; 6: 247-255.
Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjögren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren’s syndrome. Ann Rheum Dis 2010; 69: 1103-1109.
Seror R, Bowman SJ, Brito-Zeron P et al. EULAR Sjögren’s syndrome disease activity index (ESSDAI): a user guide. RMD Open 2015; 1: e000022.
Ramos-Casals M, Brito-Zeron P, Camps MT, et al. Systemic involvement in primary Sjogren’s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology (Oxford) 2014; 53: 321-331.
Garcia-Carrasco M, Cervera R, Rosas J, et al. Primary Sjögren’s syndrome in the elderly: clinical and immunological characteristics. Lupus 1999; 8: 20-23.
Haugen AJ, Peen E, Hulten B, et al. Estimation of the prevalence of primary Sjögren syndrome in two age-different community-based population using two sets of classification criteria: the Hordaland Health Study. Scand J Rheumatol 2008; 37: 30-34.
Botsios C, Furlan A, Ostuni P, et al. Elderly onset of primary Sjögren symdrome: clinical manifestations, serological features and oral/ocular diagnostic tests. Comparison with adult and young onset of the disease in a cohort of 336 Italian patients. Joint Bone Spine 2011; 78: 171-174.
Chebbi W, Ben-Salem W, Klii R, et al. Primitive Sjögren syndrome in the elderly: clinical and immunological characteristics. Pan Afr Med J 2015; 20: 8.
Tishler M, Yaron I, Shirazi I, Yaron M. Clinical and immunological characteristics of elderly onset Sjögren’s syndrome: a comparison with younger onset disease. J Rheumatol 2001; 28: 795-797.
Bunim JJ, Talal N. Development of malignant lymphoma in the course of Sjögren’s syndrome. Trans Assoc Am Physicians 1963; 76: 45-56.
Kassan SS, Thomas TL, Moutsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. Am Intern Med 1978; 89: 888-892.
Papageorgoiu A, Mavragani CP, Nezoa A, et al. Predicting the outcome of Sjögren’s syndrome-associated non-Hodgkin’s lymphoma patients. PLoS One 2015; 10: e0116189.
Johnsen SJ, Brun JG, Goransson LG, et al. Risk of non-Hodgkin’s lymphoma in primary Sjögren’s syndrome: a population based-study. Arthritis Care Res (Hoboken) 2013; 65: 816-821.
Yadlapati S, Efthimiou P. Autoimmune/Inflammatory arthritis associated lymphomas: Who is at risk? Biomed Res Int 2016; 2016: 8631061.
Zhang W, Feng S, Yan S, et al. Incidence of malignancy in primary Sjögren’s syndrome in a Chinese cohort. Rheumatology 2010; 49: 571-577.
Valesini G, Priori R, Bavoillot D, et al. Differential risk of non-Hodgkin’s lymphoma in Italian patients with primary Sjögren’s syndrome. J Rheumatol 1997; 24: 2376-2380.
Lazarus MN, Robinson D, Mak V, et al. Incidence of cancer in a cohorts of patient with primary Sjogren syndrome. Rheumatology (Oxford) 2006; 45: 1012-1015.
Fragkioudaki S, Mavragani CP, Moutsopoulos HM. Predicting the risk for lymphoma development in Sjogren syndrome: an easy tool for clinical use. Medicine (Baltimore) 2016; 95: e3766.
Nocturne G, Virone A, Ng WF, et al. Rheumatoid factor and disease activity are independent predictors of lymphomas in primary Sjogren’s syndrome. Arthritis Rheum 2016; 68: 977-985.
Repetto L, Luciani A. Cancer treatment in elderly patients: evidence and clinical research. Recenti Prog Med 2015; 106: 23-27.
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009; 6: e1000097.
Abrol E, Gonzales-Pulido C, Praena-Fernandez JM, Isenberg DA. A retrospective study of long-term outcomes in 152 patients with primary Sjögren’s syndrome: 25-year experience. Clin Med 2014; 14: 157-164.
Weng MY, Huang YT, Liu MF, Lu TH. Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjögren’s syndrome in Taiwan. Ann Rheum Dis 2012; 71: 524-527.
Boussios S, Pentheroudakis G, Somarakis G, et al. Cancer diagnosis in a cohort of patients with Sjögren’s syndrome and rheumatoid arthritis: a single-center experience and review of the literature. Anticancer Res 2014; 34: 6669-6676.
Theander E, Henriksson G, Ljungberg O, et al. Lymphoma and other malignancies in primary Sjogren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006; 65: 796-803.
Liang Y, Yang Z, Qin B, Zhong R. Primary Sjögren’s syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis 2014; 73: 1151-1156.
Lai WS, Liu FC, Wang CH, Chen HC. Unusual cancer in primary Sjögren syndrome. Can Fam Phys 2014; 60: 912-915.
Moutsopoulos HM, Steinberg AD, Fauci AS, et al. High incidence of free monoclonal light chains in the sera of patients with Sjogren syndrome. J Immunol 1983; 130: 2663-2665.
Tazi I, Rachid M, Benchekroun S. Sjögren syndrome associated with multiple myeloma. Singapore Med J 2008; 49: e215.
Ota T, Wake A, Eto S, Kobayashi T. Sjögrens syndrome terminating with multiple myeloma. Scand J Rheumatol 1995; 24: 316-318.
Tomi AL, Belkhir R, Nocturne G, et al. Brief report: Monoclonal gammopathy and risk of lymphoma and multiple myeloma in patients with primary Sjögren’s syndrome. Arthritis Rheum 2016; 68: 1245-1250.
Sutcliffe N, Inanc M, Speight P, Isenberg D. Predictors of lymphoma development in primary Sjögren’s syndrome. Semin Arthritis Rheum 1998; 28: 80-87.
Yu KH, Kuo CF, Huang LH, et al. Cancer risk in patients with inflammatory systemic autoimmune rheumatic diseases. Medicine (Baltimore) 2016; 95: e3540.
Gadalla SM, Amr S, Langenberg P, et al. Breast cancer in elderly women with systemic autoimmune rheumatic diseases: a population-based case-control study. Br J Cancer 2009; 100: 817-821.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Journals System - logo
Scroll to top